Abstract:BACKGROUND:Hepatocellular carcinoma (HCC) is one of the most common malignant tumors with poor prognosis. Various chemotherapeutics are used in treatment of HCC, but most of them have significant toxicity to patients. Thus, it is urgently needed to develop new therapeutic strategies to achieve high specificity and tolerable adverse effects. As a natural polyphenol, ellagic acid (EA) demonstrates inhibitory effects in cancers.PURPOSE:The goal of the present study to investigate the anticancer activity of EA with a focus on its stimulating effects on doxorubicin hydrochloride (DOX) and cisplatin (DDP) in HCC treatment.METHODS:HepG2, SMMC-7721 and HL-7702 cells were treated with EA, DOX, DDP or their combinations. Cell viability and apoptosis were examined to evaluate the cytotoxicity of these treatments. Western blot analysis and immunofluorescent assays were used to determine expression of genes related to the mitochondrial apoptosis pathway. To assess the anticancer activities and systemic toxicity of EA, DOX and EA+DOX treatments, a xenograft mouse model with inoculated HepG2 cells was employed, followed by immunohistochemical and histopathological evaluation.RESULTS:EA could both markedly potentiate anticancer activities of DOX and DDP to HCC HepG2 and SMMC-7721 cells, and reduce their cytotoxicity to normal liver HL-7702 cells. EA and its combination with DOX or DDP induced cell apoptosis through a pathway mediated by mitochondrial cytochrome c release. In nude mice, EA combination with a relatively low dosage of DOX effectively inhibited tumor growth without causing cardiotoxicity observed in mice treated by a high dosage of DOX.CONCLUSION:We discovered that EA synergistically potentiated DOX and DDP in suppressing HCC with significantly reduced side effects and this may represent a novel strategy in HCC therapies with both high anticancer efficiencies and low systemic toxicity in patients.

Research Progress on the Anticarcinogenic Mechanisms of Ellagic Acid

The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art

Research Progress in Anticancer Mechanism of Epigallocatechin Gallate(egcg)

Exploring the Potential of Ellagic Acid in Gastrointestinal Cancer Prevention: Recent Advances and Future Directions

Synergism of Ellagic Acid in Combination with Radiotherapy and Chemotherapy for Cancer Treatment

Research Progress on the Anticancer Effect and Mechanism of Gardenia jasminoides Ellis

The potential inhibition effect of ellagic acid on liver cells in the treatment of hepatocellular carcinoma

Resveratrol: an Overview of Its Anti-Cancer Mechanisms

Antitumor effect and mechanism of an ellagic acid derivative on the HepG2 human hepatocellular carcinoma cell line.

Gallic Acid: A Potential Anti-Cancer Agent

Insights into the anticancer effects of galangal and galangin: A comprehensive review

Research Progress in Ellagitannin Compounds

Ellagic Acid, a Phenolic Compound, Exerts Anti-Angiogenesis Effects Via VEGFR-2 Signaling Pathway in Breast Cancer

Icariin as a potential anticancer agent: a review of its biological effects on various cancers

Advances In Research On The Anticancer Mechanism Of The Natural Compound Cucurbitacin From Cucurbitaceae Plants: A Review

Research Progress on the Anticancer Activities and Mechanisms of Polysaccharides From Ganoderma

The Potential of Epigallocatechin Gallate in the Chemoprevention and Therapy of Hepatocellular Carcinoma

Ellagic Acid Synergistically Potentiates Inhibitory Activities of Chemotherapeutic Agents to Human Hepatocellular Carcinoma.

Anticancer potential of emodin

The potential of epigallocatechin gallate in the chemoprevention and therapy of hepatocellular carcinoma.

The anticancer effects of curcumin and clinical research progress on its effects on esophageal cancer